Tim Henkel

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Urinary Tract Infection

Top Venues

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
James A Dowell, Thomas C Marbury, William B Smith, Tim Henkel
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment. Antimicrobial agents and chemotherapy 66 (9) (2022)
James A Dowell, Daniel Dickerson, Tim Henkel
Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor. Antimicrobial agents and chemotherapy 65 (11) (2021)